BioSpace News Archive

Today, Biogen Inc. (Nasdaq: BIIB) announced positive top-line results from the Phase 2 LILAC study evaluating the efficacy and safety of BIIB059, a fully humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) expressed on plasmacytoid dendritic cells, in patients with lupus.

MediWound Ltd. (the “Company”) (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the initiation of patient treatment in its U.S. Phase 2 adaptive design clinical study of EscharEx, a topical biologic drug candidate designed to enzymatically debride chronic wounds, for the treatment of venous leg ulcers (VLU’s).

Willow Biosciences Inc., a Canadian biotechnology company and a leading developer in biosynthetically produced cannabidiol, comments on Purisys, LLC’s news release issued on November 21st stating that the U.S. Drug Enforcement Agency has removed Purisys’ CBD from Schedule I of the Controlled Substances Act.

Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 million with Aspire Capital Fund, LLC (“Aspire Capital”), a Chicago-based institutional investor.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Heron’s New Drug Submission (NDS) for HTX-011 for the management of postoperative pain was granted Priority Review status and accepted by Health Canada

KalVista Pharmaceuticals, Inc. provided an operational update and released financial results for the fiscal second quarter ended October 31, 2019.

Bristol-Myers Squibb Company and Acceleron Pharma Inc. today announced the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers Squibb’s supplemental Biologics License Application for the use of Reblozyl® in patients with myelodysplastic syndromes at its meeting on December 18, 2019.

The Company partners with Reified Capital, a provider of advanced artificial intelligence-focused technical advisory services to the private sector

Novel Organ-Selective Pan-JAK Inhibitor Specifically Designed to Target Airway Inflammation in the Lung With Minimal Systemic Exposure Allergen Challenge Study Expected to Provide Key Insights to Support Ongoing Clinical Development of TD-8236

OWP Pharmaceuticals, Inc. announced that it has received Investigational New Drug approval from the U.S. Food and Drug Administration, and has submitted for U.S. patent protection, for the first-ever liquid formulation of lamotrigine.